Granules India enters CDMO business by acquiring Senn Chemicals AG

The acquisition marks Granules foray into CDMO segments, leveraging Senn’s existing CDMO business and customer relationships

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Granules India Limited on Friday announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. The company said that this acquisition enables Granules’ acquiring capabilities into high-growth peptide-based therapeutics. "The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics," the company said in a statement.

Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services. The closing of the acquisition is subject to certain conditions. The closing is expected to occur in the first half of 2025. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn’s R&D capabilities, it said in a statement.

The acquisition brings Senn’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationships, including innovators and brand owners across pharma, cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments.

"Senn’s manufacturing facility is certified under ISO 9001:2015 and is regularly inspected and approved for cGMP production by Swissmedic." Under the Mutual Recognition Agreement (MRA) between Swissmedic and the U.S. Food and Drug Administration (FDA), cGMP inspections conducted by Swissmedic are recognized by the FDA.

The acquisition marks Granules' foray into CDMO segments, leveraging Senn’s existing CDMO business and customer relationships, on the back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics.

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said "The acquisition of Senn Chemicals AG marks a significant milestone in Granules' strategic growth journey. By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability. Senn’s expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally. This acquisition is a pivotal moment in our vision to transform Granules to a science and innovation led organization and become a trusted partner in complex and specialized therapeutics."

Dr. Rico Wiedenbruch, Chairman, Senn Chemicals AG, said "We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation. With Granules’ scale, operational efficiency, and global reach in pharmaceuticals industry, we see a strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics. This partnership strengthens our ability to serve our customers with best-in-class CDMO solutions while driving innovation in peptide development and manufacturing."